PFIZER INC is reviewing its planned investments in Germany after government proposals to lower drug prices. This review follows similar investment cuts by ELI LILLY & CO and Boehringer Ingelheim. CEO Albert Bourla warned that the policies threaten the predictability required for long-term pharmaceutical commitments.

Pricing Policies Threaten Capital Expenditure